Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

NCT02889900 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Platinum Resistant Ovarian Cancer

Interventions

DRUG: cediranib and olaparib

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]